198. Thalidomide Scandal: The Price of Blind Trust in Health Advice

In this podcast episode, we’re learning about one of the largest pharmaceutical disasters in modern history: the Thalidomide scandal. We’re exploring how a medicine that is marketed as safe and revolutionary becomes responsible for thousands of devastating birth defects around the world and how this tragedy fundamentally changes drug safety forever.Moreover, we’re examining a question that is surprisingly relevant decades later: Why do people continue trusting health claims without sufficient evidence? From miracle cures to questionable wellness advice on social media, history repeatedly demonstrates how hope, fear, marketing and authority can influence our health decisions.This episode is not merely about the past. It is about you, beautiful. It is about understanding how scientific evidence works, why skepticism is a form of self-care, and how you can confidently navigate health trends in the age of TikTok, Instagram, YouTube and artificial intelligence.If you’ve ever wondered whom to trust when it comes to your health, love, this episode is for you.I would love hearing your opinion and, if applicable, your personal experience with this topic. Please send me an e-mail at coucou.goddess@gmail.com.REFERENCESAmerican Lung Association (2026) Health TikTok Trends: Which Ones Are Safe and Which Ones Are Dangerous?BBC News (2011) The women behind the thalidomide scandal.Dana-Farber Cancer Institute (2018) After 60 Years, Scientists Uncover How Thalidomide Produced Birth Defects.Frontiers in Public Health (2026) Health misinformation and social media trends.Guardian (2012) Thalidomide scandal timeline.McBride, W.G. (1961) Thalidomide and congenital abnormalities. The Lancet.Science Museum (2026) Thalidomide.Stephens, T.D. and Brynner, R. (2001) Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine.Thalidomide Trust (2026) About Thalidomide.Vargesson, N. (2011) Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Research Part C.